1114 GMT - Evonik posted a robust and solid set of numbers that came in line with expectations, Morgan Stanley analysts say in a research note. The German specialty-chemicals company saw both adjusted Ebitda and free-cash-flow figures ahead of Visible Alpha estimates. The company also backed its guidance for 2025 adjusted Ebitda in a range between 2.0 billion and 2.3 billion euros. "We judge that second-quarter Visible Alpha consensus [for adjusted Ebitda] at 574 million euros is likely secure given the trends in methionine but note this looks low vs normal seasonality," they say. Shares trade 1.39% higher at 20.08 euros. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 07:14 ET (11:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.